Navigation Links
338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment
Date:9/4/2008

SAN MATEO, Calif., Sept. 4 /PRNewswire-FirstCall/ -- BioForm Medical, Inc. (Nasdaq: BFRM) today announced that the pivotal clinical study of Polidocanol, conducted in Germany by BioForm Medical's partner, Chemische Fabrik KREUSSLER & Co. GmbH (Kreussler), successfully met the study primary endpoint and has been submitted to FDA as part of a New Drug Application (NDA) process.

In the pivotal clinical study, named the EASI (Efficacy and safety of Aethoxysklerol compared to Sodium Tetradecyl Sulfate and Isotonic Saline) study, 338 patients with C1 varicose veins (either spider veins of <1mm diameter or reticular veins of 1-3mm diameter), were randomized to receive either Polidocanol (also called Lauromacrogol 400, European tradename, Aethoxysklerol(R)), Sodium-tetradecyl-sulfate (STS or Sotradecol(R), an effective control), or Isotonic saline (a placebo control). Patients were followed for 26 weeks (6 months) with standardized photography of a defined 10x10 cm area of the leg at baseline, 12 weeks and 26 weeks. These photographs were rated by the treating physicians and two blinded evaluators, which served as the basis for efficacy assessment.

The EASI study successfully met its primary efficacy endpoint with demonstrated statistically significant superiority (p<0.0001) of Polidocanol versus placebo. The treatment success rates for Polidocanol were 96% and 95% at 12 and 26 weeks, compared to STS (92%, 91%) and placebo (8%, 6%). A secondary endpoint analysis demonstrated that significantly more patients were satisfied or very satisfied with Polidocanol at 12 or 26 weeks (88%, 84%), compared to STS (63%, 64%; p<0.0001) or placebo (13%, 11%; p<0.0001). Polidocanol was found to be safe and well tolerated in the study. The incidence
'/>"/>

SOURCE BioForm Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients
2. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
3. Agendia Launches TargetPrint(R) for Breast Cancer Patients
4. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
5. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
6. Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
7. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
8. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
9. n-3 PUFAs Reduce Mortality and Hospital Admissions in Patients With Symptomatic Heart Failure
10. TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated With Second-Generation TAXUS(R) Liberte(R) Stent
11. Calabar AB Today Announced New Financing for Continuation of the Phase II Program in Patients With Dry Mouth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  SiteOne Therapeutics Inc. today ... financing. Led by Sears Capital Management and Biobrit LLC, ... Zakrzewski , the $1.5 million financing positions SiteOne to ... pain and to further develop its technology platform for ... In conjunction with the financing, Lowell ...
(Date:9/23/2014)... According to the new ... Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave), Application (General & ... Forecasts to 2019", published by MarketsandMarkets, studies the global ... 2014 to 2019. The market is expected to ... 9.6% from 2014 to 2019. Browse ...
(Date:9/23/2014)... , Sept. 23, 2014 CASI Pharmaceuticals, ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a primary focus on ... Rajesh C. Shrotriya , MD, Chairman and Chief Executive ... Directors.  The appointment was made in connection with the ...
Breaking Medicine Technology:SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 4CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 3CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 4
... 2010 Diopsys, Inc. today announced the development of ... (SD-OCT) images to assist ophthalmologists and optometrists in diagnosing ... SD-OCT is an imaging technique used to ... Nerve Fiber Layer (RNFL) which can help them diagnose ...
... 20, 2010 A small Midwest college that is producing ... a $35 million grant from Lilly Endowment to launch a ... northern Indiana, has a Nobel Laureate in chemistry, the inventor ... and the first female commissioner of the U.S. Food and ...
Cached Medicine Technology:New Software for Improving the Analysis of OCT Images 2Manchester College Receives $35 Million Grant From Lilly Endowment for School of Pharmacy 2Manchester College Receives $35 Million Grant From Lilly Endowment for School of Pharmacy 3
(Date:9/23/2014)... (PRWEB) September 23, 2014 AmerisourceBergen’s ... Canadian specialty market, is now providing U.S. manufacturers ... new 160,000-square-foot distribution center coupled with its fully-licensed ... healthcare industry has historically been difficult for smaller ... government regulation complexities. As a result of these ...
(Date:9/23/2014)... 23, 2014 The print component of ... Metro, with a circulation of approximately 327,720 copies and ... distributed nationally through a vast social media strategy and ... outlets. To explore the digital version of the campaign, ... exclusive interview with Michael Landsberg, host of TSN’s Off ...
(Date:9/23/2014)... WASHINGTON, Sept. 23, 2014 Antibiotics revolutionized health ... bacteria that once killed thousands of people. But ... strains of antibiotic-resistant bacteria are popping up more ... the current shortage of new antibiotics and discusses ... answers the question: Why should you finish your ...
(Date:9/23/2014)... Ind. -- Contrary to what is often assumed about ... new study from The Kinsey Institute has found that ... are sexually active as often as singles without children ... children. , The study, "Dating and Sexual Behavior Among ... was published online in the Journal of Sex ...
(Date:9/23/2014)... SC (PRWEB) September 23, 2014 On September ... by Keith Simmons for an episode. Simmons is the founder ... Deierlein believed the audience would like to know. At the ... get the idea to start this magazine?” Simmons replied by ... advertising sales person. In 2005, I quit that and decided ...
Breaking Medicine News(10 mins):Health News:AmerisourceBergen Paves Path to Canadian Markets 2Health News:AmerisourceBergen Paves Path to Canadian Markets 3Health News:‘Sick, not weak’: Mediaplanet’s "Mental Health” Campaign Dispels Stigmas and Bolsters Support for the One in Five Canadians Suffering Mental Illness 2Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2Health News:My Positive Perspective Airs Episode With the Founder of Traveler of Charleston Magazine 2
... scientists have been chosen from a highly competitive field ... Merck Sharp & Dohme and Advance to boost the ... Antisense Therapeutics Ltd (ASX code: ANP) Research Director Dr ... have been selected as joint winners of the 2008 ...
... important international relationships is top of the agenda ... Dr Raisa Monteiro, when she meets with leading ... One of two Australian life scientists chosen from ... prestigious 2008 Advancing BioBusiness Award, Russian-born Dr Monteiro ...
... anemia in expectant mothers and spinal birth defects in newborns, the ... has now been shown to blunt the damaging effects of heart ... In a new study, an international team of heart experts at ... daily of folate, also known as folic acid or vitamin B9, ...
... Solution for ... Employers, ... believe the future of managing health care costs lies in,helping their ... Seventh Annual Tri-State Area Employee,Benefit Survey., Cowden Associates, the region,s ...
... US$1.75 million of new available funds -, ... Inc. (TSX: BNC), a research-based, technology-driven Canadian,biopharmaceutical company, ... under the agreement to repay US$1.75 million of ... Laurus Master Funds),in common shares., The conversion ...
... ROLLA, Mo., March 27 While today,s shaky economy ... has been an,exception. In fact, there is currently a ... positions. Furthermore, according to the latest,projections from the U.S. ... replacement nurses will be needed by 2014 -- and ...
Cached Medicine News:Health News:Rising Australian biotech stars set to connect on the world stage 2Health News:DendriMed scientist seeks to fast-track success 2Health News:Folate scores a win in animal studies: Brief, high doses of B vitamin blunt damage from heart attack 2Health News:Folate scores a win in animal studies: Brief, high doses of B vitamin blunt damage from heart attack 3Health News:Folate scores a win in animal studies: Brief, high doses of B vitamin blunt damage from heart attack 4Health News:Survey Highlights Ongoing Shift To Wellness to Manage Health Care Costs 2Health News:Survey Highlights Ongoing Shift To Wellness to Manage Health Care Costs 3Health News:Bioniche Converts a Portion of its Debt to Equity 2Health News:NurseAuction.com Aims to Alleviate Nurse Shortage with Online Nurse Bidding 2
... Finntip Filters are ideal for ... or for any work where ... are designed for pipetting DNA/RNA ... and other. For applications requiring ...
Inquire...
... aerosol contamination, which causes ... PCR. Hydrophobic, nonwicking and ... can pass through these ... contrast to tips with ...
... offer a safe alternative to using positive ... applications such as PCR(a), pipetting radioactive materials ... are excellent for tissue culture, gel loading, ... prevent aerosol contaminants and liquids from reaching ...
Medicine Products: